

**PRESS RELEASE**

**2013 third-quarter revenue**

Villepinte, 23 October 2013

**Consolidated Group revenue (IFRS)**

<b>In millions of euros</b>	<b>2012</b>	<b>2013</b>	<b>Change</b>
First quarter .....	96.8	91.0	(6.0)%
Second quarter .....	102.4	101.4	(1.0)%
Third quarter .....	95.8	96.0	+ 0.2 %
<b>Total.....</b>	<b>295.0</b>	<b>288.4</b>	<b>(2.3)%</b>

**Consolidated revenue by region**

<b>In millions of euros</b>	<b>2012</b>	<b>2013</b>	<b>Change</b>
European subsidiaries.....	209.7	204.6	(2.4)%
Other markets.....	85.3	83.8	(1.8)%
<b>Total.....</b>	<b>295.0</b>	<b>288.4</b>	<b>(2.3)%</b>

**Year-to-date sales steady at constant exchange rates**

After contracting in the first two quarters, third-quarter sales came in at €96 million (+0.2%). Year-to-date, sales remained down 2.3% overall from the same period last year though steady at constant exchange rates (-0.2%). Sales in Japan and Brazil were adversely affected by very unfavourable foreign exchange trends relative to the euro.

For the first nine months, the MRI segment grew 2.6% to €122.2 million. This trend is observed both in Europe and in other markets.

Conversely, sales for X-Ray products contracted 8.9% to €133.3 million. This decline, more limited in the third quarter (-5.6%), is concentrated in Europe where the general economic situation remains uneven. This segment was furthermore adversely impacted at the year's start by an exceptionally high level of 2012 year-end sales in Europe that led to slower order intake in early 2013.

The "Other products" activity, comprised mainly of interventional radiology and medical devices, generated revenue of €32.9 million, gaining 11.4%.

At 30 September, the strongest performances were registered in Asia and the United States.

In the latter, Dotarem's first months on the market showed very positive momentum notably with an order of one million dollars. Also in the United States, the FDA granted Lipiodol the Orphan Drug designation. An application for extending the indication has moreover been filed and is currently under review.

**Contact:** Administrative and Finance Department - Tel.: +33 (0)1 45 91 50 69